Gene Information
Gene Symbol
MIRN155, miRNA155, mir-155
Entrez Gene ID
Gene Name
MicroRNA 155
Chromosomal Location
microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop. [provided by RefSeq, Sep 2009]

Gene Ontology (GO)

GO ID Ontology Function Evidence Reference
GO:0001818 Biological process Negative regulation of cytokine production IDA 24885259
GO:0010628 Biological process Positive regulation of gene expression IDA 24885259
GO:0010628 Biological process Positive regulation of gene expression IMP 30031401
GO:0010629 Biological process Negative regulation of gene expression IDA 19193853
GO:0010629 Biological process Negative regulation of gene expression IMP 19193853, 21030878, 27731397

MicroRNAs in cancer


Associated Diseases

Disease groupDisease NameReferences
Digestive System Diseases
Endocrine System Diseases
Lung Cancer
Carcinoid Tumor
PubMed ID Associated gene/s Associated condition Genetic Mutation Diagnostic Criteria Association with PCOS Ethnicity Conclusion
D4-androstenedione, dehydroepiandrosterone sulfate (DHEAS), 17-hydroxyprogesterone (17OHpg), follicle-stimulating hormone (FSH), luteinizing hormone (LH), 17-betha-estradiol (17-b-E2) 
PCOS, Biochemical and clinical hyperandrogenism, menstrual and ovulatory dysfunctions and polycystic ovaries with exclusion of other androgenic, pituitary or adrenal causes, insulin resistance, hyperinsulinemia, type 2 diabetes, dyslipidemia and cardiovas 
Rotterdam criteria 
16 Caucasian women of reproductive age who suffered from PCOS 
We suggest that miR-155 level in sera might be used as a noninvasive biomarker to monitor the response to estroprogestinic therapy in hyperandrogenic PCOS patients. 

| © 2019, Biomedical Informatics Centre, NIRRH |
National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai-400 012
Tel: 91-22-24192104, Fax No: 91-22-24139412